- Home
- EDRY vs GDTC Comparison
EDRY vs GDTC Comparison
Compare EDRY & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- GDTC
- Stock Information
- Founded
- EDRY 2018
- GDTC 2018
- Country
- EDRY Greece
- GDTC Singapore
- Employees
- EDRY N/A
- GDTC N/A
- Industry
- EDRY Marine Transportation
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- GDTC Health Care
- Exchange
- EDRY Nasdaq
- GDTC Nasdaq
- Market Cap
- EDRY 27.3M
- GDTC 21.5M
- IPO Year
- EDRY N/A
- GDTC 2023
- Fundamental
- Price
- EDRY $12.02
- GDTC $2.27
- Analyst Decision
- EDRY
- GDTC Buy
- Analyst Count
- EDRY 0
- GDTC 1
- Target Price
- EDRY N/A
- GDTC $5.00
- AVG Volume (30 Days)
- EDRY 2.1K
- GDTC 13.1K
- Earning Date
- EDRY 08-11-2025
- GDTC 01-01-0001
- Dividend Yield
- EDRY N/A
- GDTC N/A
- EPS Growth
- EDRY N/A
- GDTC N/A
- EPS
- EDRY N/A
- GDTC N/A
- Revenue
- EDRY $49,707,775.00
- GDTC $368,838.00
- Revenue This Year
- EDRY N/A
- GDTC $5.37
- Revenue Next Year
- EDRY $28.45
- GDTC N/A
- P/E Ratio
- EDRY N/A
- GDTC N/A
- Revenue Growth
- EDRY N/A
- GDTC N/A
- 52 Week Low
- EDRY $7.60
- GDTC $1.20
- 52 Week High
- EDRY $20.80
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- EDRY 70.05
- GDTC 70.54
- Support Level
- EDRY $10.70
- GDTC $1.82
- Resistance Level
- EDRY $11.54
- GDTC $2.07
- Average True Range (ATR)
- EDRY 0.21
- GDTC 0.10
- MACD
- EDRY 0.11
- GDTC 0.03
- Stochastic Oscillator
- EDRY 100.00
- GDTC 100.00
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.